Get the Stockscreener App
2.68
8.38%
-0.245
Pre-market:
2.80
0.12
+4.48%
Hcw Biologics Inc stock is traded at $2.68, with a volume of 129.28K.
It is down -8.38% in the last 24 hours and down -40.44% over the past month.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
See More
Previous Close:
$2.925
Open:
$3.1853
24h Volume:
129.28K
Relative Volume:
0.07
Market Cap:
$4.28M
Revenue:
$6.59M
Net Income/Loss:
$-18.12M
P/E Ratio:
-0.2833
EPS:
-9.4605
Net Cash Flow:
$-11.45M
1W Performance:
-21.41%
1M Performance:
-40.44%
6M Performance:
-31.29%
1Y Performance:
-89.71%
1-Day Range:
$2.5801
$3.25
1-Week Range:
$2.5801
$3.67
52-Week Range:
$1.50
$44.10
Hcw Biologics Inc Stock (HCWB) Company Profile
Name
Hcw Biologics Inc
Sector
Industry
Phone
954-842-2024
Address
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
2.68 | 5.02M | 6.59M | -18.12M | -11.45M | -9.4605 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Hcw Biologics Inc Stock (HCWB) Latest News
HCW Biologics Q2 net loss widens to $5.2M despite revenue surge - scanx.trade
Form 8K HCW Biologics Inc For: 14 August By Investing.com - Investing.com Nigeria
HCW Biologics Inc. Q2 2026: Revenue $135.6K, EPS $(11.58) — 10-Q Summary - TradingView
HCW Biologics Reports Second Quarter 2026 Financial Results and Updates HCW9302 Alopecia Areata Program, HCW11-018b Development and Financing Activities - Quiver Quantitative
HCW Biologics trial: 3 alopecia patients cut SALT scores 25%+ - Stock Titan
HCW Biologics Inc (HCWB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HCW Biologics (HCWB) completes $1.6M exempt equity and warrant sale - Stock Titan
HCW Biologics | D: Filing D - Moomoo
HCWB Q2'26 Earnings: EPS estimate is (1.98) USD - TradingView
Price to earnings forward of HCW Biologics Inc. – NASDAQ:HCWB - TradingView
HCW Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Flowers Lee - Moomoo
HCW Biologics Announces $1.6 Million Private Placement Financing - The Globe and Mail
HCW Biologics Raises $1.6 Million in Private Placement; Units Priced at $2.585 - TradingView
HCW Biologics Prices $1.6 Million Private Placement Offering - marketscreener.com
HCWB Looks 94.1% Undervalued on GF Value™ Amid Challenging Funda - GuruFocus
HCW Biologics prices $1.6M private placement offering By Investing.com - Investing.com Canada
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering - globenewswire.com
HCWB|HCW Biologics Inc|Price:2.640|Chg%:+0.140 - TradingKey
HCW Biologics Inc (HCWB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
HCW Biologics Inc (HCWB) Cash Flow - TradingKey
HCW Biologics (HCWB) Surges 6% as Shares Test Key Resistance Near $2.78Double EMA - dars.gov.et
HCW Biologics Inc (HCWB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
HCW Biologics Inc (HCWB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
HCW Biologics Q1 2026 Earnings: Massive EPS Beat but Stock Plunges – Market Skepticism Over SustainabilityEPS Surprise History - dars.gov.et
TradingKey - TradingKey
HCWB|HCW Biologics Inc|Price:2.500|Chg%:-0.380 - TradingKey
HCW Biologics Inc (HCWB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
HCW Biologics Inc (HCWB) Valuation: PE, PB & Fair Value Analysis - TradingKey
HCW Biologics Inc. Revenue Breakdown – NASDAQ:HCWB - TradingView
HCW Biologics Inc. (HCWB) Stock Price, News, Quote & History - Yahoo! Finance Canada
HCW Biologics seeks pre-IND meeting with FDA for HCW-11-018b - BioWorld News
HCW Biologics Inc. (HCWB) stock price, news, quote and history - Yahoo Finance UK
HCW Biologics’ Cancer Candidate Targets Tissue Factor in Solid Tumors - Stock Titan
HCW Biologics requests FDA meeting for HCW11-018b solid tumor candidate - scanx.trade
HCWB Q1 2026 Earnings: Strong EPS Beat Despite Zero Revenue; Stock DeclinesManagement Tone Analysis - dars.gov.et
HCW Biologics Q1 2026 Earnings: Positive EPS Surprise Overwhelmed by Revenue AbsenceEarnings Beat Alert - dars.gov.et
HCW Biologics (HCWB) seeks $5.6M in stock sale to fund trials, repay debt - Stock Titan
HCWB Q1 2026 Earnings: EPS Surge on Non-Operating Items Overshadows Lack of RevenueBalance Sheet Strength - dars.gov.et
HCW Biologics Inc. Q1 2026 Earnings: Surprise EPS Beat Amidst No RevenuePre-Earnings Drift - DonanımHaber
HCW Biologics (HCWB) Declines 3.25% as Shares Approach Key Support LevelDealer Positioning - dars.gov.et
MSN Money - MSN
HCW Biologics (HCWB) Drops 8%: Testing Support Levels After Sharp DeclineSynthetic Long - dars.gov.et
HCW Biologics Regains Nasdaq Compliance, Plans Reverse Split - The Globe and Mail
HCW Biologics (HCWB) clears $2.8M disputes and $1.1M lien - Stock Titan
HCW Biologics Inc.: Top Mutual Funds Holders | QNCX | US40423R3030 - marketscreener.com
HCW Biologics Inc.: Fundamental Analysis and Financial Ratings | QNCX | US40423R3030 - marketscreener.com
HCW Biologics Inc.: Dividend historical data and projections - marketscreener.com
HCW Biologics regains Nasdaq compliance, plans stock split - Investing.com UK
HCW Biologics to Implement 1-for-6 Reverse Stock Split - Moomoo
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter - Investing News Network
HCW Biologics regains Nasdaq compliance, plans stock split By Investing.com - Investing.com Nigeria
Hcw Biologics Inc Stock (HCWB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):